(Q46482938)

English

Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).

scientific article published in June 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15885045

Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). (English)

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15885045

0 references

author name string

J Haas

1

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15885045

M Firzlaff

2

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15885045

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 June 2005

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15885045

European Journal of Neurology

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15885045

12

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15885045

6

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15885045

425-431

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15885045

A comparison of observational studies and randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.00936.X

21 January 2018

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.00936.X

21 January 2018

Randomized, controlled trials, observational studies, and the hierarchy of research designs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.00936.X

21 January 2018

Axonal damage in acute multiple sclerosis lesions.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.00936.X

21 January 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.00936.X

21 January 2018

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.00936.X

21 January 2018

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.00936.X

21 January 2018

Systematic reviews in health care: Assessing the quality of controlled clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.00936.X

21 January 2018

A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.00936.X

21 January 2018

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.00936.X

21 January 2018

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.00936.X

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.00936.X

21 January 2018

Identifiers

10.1111/J.1468-1331.2005.00936.X

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15885045

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15885045

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46482938&oldid=1624761988"